ABT-199 and Ibrutinib Combination
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell
Trial Timeline
Apr 1, 2015 → May 1, 2021
NCT ID
NCT02419560About ABT-199 and Ibrutinib Combination
ABT-199 and Ibrutinib Combination is a phase 1 stage product being developed by AbbVie for Lymphoma, Mantle-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT02419560. Target conditions include Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02419560 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma, Mantle-Cell